ES2111524T3 - Peptidos de eritropoyetina (epo) y anticuerpos dirigidos contra ellos. - Google Patents

Peptidos de eritropoyetina (epo) y anticuerpos dirigidos contra ellos.

Info

Publication number
ES2111524T3
ES2111524T3 ES90113527T ES90113527T ES2111524T3 ES 2111524 T3 ES2111524 T3 ES 2111524T3 ES 90113527 T ES90113527 T ES 90113527T ES 90113527 T ES90113527 T ES 90113527T ES 2111524 T3 ES2111524 T3 ES 2111524T3
Authority
ES
Spain
Prior art keywords
epo
antibodies
peptides
epitope
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90113527T
Other languages
English (en)
Inventor
Mathias Dr Fibi
Werner Dr Stueber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behring Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behring Diagnostics GmbH filed Critical Behring Diagnostics GmbH
Application granted granted Critical
Publication of ES2111524T3 publication Critical patent/ES2111524T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

EL INVENTO CONCIERNE A LOS PEPTIDOS DE ERITROPOYETINA (EPO) Y A SU UTILIZACION PARA LA OBTENCION DE ANTICUERPOS EPITOPESPECIFICOS ANTI-EPO, LOS CUALES PUEDEN SER POLICLONES (ANTISUEROS) O MONOCLONES. TAMBIEN SE REFIERE EL INVENTO AL USO DE DICHOS ANTICUERPOS PARA LA PURIFICACION DEL EPO, DE LOS DERIVADOS DEL EPO O DE LOS EPO-PEPTIDOS. CONCIERNE TAMBIEN A LOS ANTICUERPOS ANTIIDIOTIPOS QUE IMITAN UNA ZONA RECEPTORA DEL EPO. POR ULTIMO, SE REFIERE A LA UTILIZACION DE REFIERE A LA UTILIZACION DE LOS ANTICUERPOS EPITOPESPECIFICOS ANTI-EPO PARA DETECTAR LA PRESENCIA DE EPO EN MEDICAMENTOS QUE CONTENGAN LOS CITADOS ANTICUERPOS Y PARA DIAGNOSTICAR LA PRESENCIA DE EPO O DE ANTICUERPOS ANTI-EPO.
ES90113527T 1989-07-26 1990-07-14 Peptidos de eritropoyetina (epo) y anticuerpos dirigidos contra ellos. Expired - Lifetime ES2111524T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3924746A DE3924746A1 (de) 1989-07-26 1989-07-26 Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper

Publications (1)

Publication Number Publication Date
ES2111524T3 true ES2111524T3 (es) 1998-03-16

Family

ID=6385895

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90113527T Expired - Lifetime ES2111524T3 (es) 1989-07-26 1990-07-14 Peptidos de eritropoyetina (epo) y anticuerpos dirigidos contra ellos.

Country Status (13)

Country Link
US (2) US5106954A (es)
EP (1) EP0410246B1 (es)
JP (1) JP3155002B2 (es)
KR (1) KR0175657B1 (es)
AT (1) ATE161577T1 (es)
AU (1) AU648506B2 (es)
CA (1) CA2021912C (es)
DE (2) DE3924746A1 (es)
DK (1) DK0410246T3 (es)
ES (1) ES2111524T3 (es)
GR (1) GR3026096T3 (es)
IE (1) IE902707A1 (es)
PT (1) PT94813B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6932968B1 (en) * 1989-07-26 2005-08-23 Dade Behring Marburg Gmbh Erythropoietin (EPO) peptides and antibodies directed against these
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
GB2270695B (en) * 1992-09-18 1996-06-05 Oxford Res Support Co Ltd Antibodies that activate plasminogen in the manner of streptokinase
US5830851A (en) * 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
HUP9901069A2 (hu) * 1995-06-07 1999-07-28 Affymax Technologies, N.V. Az eritropoietin receptorhoz kötődő vegyületek és peptidek
KR100400637B1 (ko) * 1996-02-06 2004-03-10 씨제이 주식회사 생물학적으로유용한펩타이드
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
TR200001580T2 (tr) * 1997-12-03 2000-12-21 Roche Diagnostics Gmbh Spesifik etkinliği yüksek eritropoyetin
KR100524041B1 (ko) * 1999-05-07 2005-10-27 제넨테크, 인크. 신규 침팬지 에리쓰로포이에틴 (chepo) 폴리펩티드 및 이를 코딩하는 핵산
IL145785A0 (en) * 1999-05-07 2002-07-25 Genentech Inc Novel chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same
US6831060B2 (en) 1999-05-07 2004-12-14 Genentech, Inc. Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
US7312089B2 (en) * 2000-04-05 2007-12-25 Jong Y. Lee Detection of erythropoietin and erythropoietin receptor
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
CA2405557C (en) 2000-04-12 2013-09-24 Human Genome Sciences, Inc. Albumin fusion proteins
CA2437272A1 (en) * 2001-02-06 2002-08-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified erythropoietin (epo) with reduced immunogenicity
WO2002070009A1 (fr) * 2001-02-27 2002-09-12 Yasuda, Yoshiko Medicaments preventifs/curatifs pour cicatrices hypertrophiques, cheloides et maladies arthritiques chroniques
CA2446739A1 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
US7045546B2 (en) * 2001-07-26 2006-05-16 Tagra Biotechnologies Ltd. Stabilized derivatives of ascorbic acid-3-phosphate
US6930086B2 (en) 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
AU2002364587A1 (en) * 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP2261250B1 (en) * 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
PL372862A1 (en) * 2002-08-09 2005-08-08 Merck Patent Gmbh T-cell epitopes in erythropoietin
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
CA2521273A1 (en) * 2003-04-02 2004-10-21 Epimmune Inc. Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
US20040266993A1 (en) * 2003-06-30 2004-12-30 Evans Glen A. Non-immunoglobulin binding polypeptides
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
US20050255112A1 (en) * 2004-05-17 2005-11-17 Lee Jong Y Compositions and methods for preventing erythropoietin-associated hypertension
MX2007005640A (es) * 2004-11-10 2007-08-14 Aplagen Gmbh Moleculas que promueven la hematopoyesis.
KR20070092706A (ko) * 2004-11-10 2007-09-13 아플라겐 게엠베하 조혈을 촉진하는 분자
US7589063B2 (en) * 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
EP1848461A2 (en) * 2005-02-16 2007-10-31 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
US8329652B2 (en) * 2005-05-10 2012-12-11 Neoloch Aps Neuritogenic peptides
EP1736481A1 (en) * 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
EP1907417A2 (en) * 2005-06-23 2008-04-09 AplaGen GmbH Supravalent compounds
PT2540309T (pt) 2005-08-05 2017-12-29 Araim Pharmaceuticals Inc Péptidos protectores de tecidos e suas utilizações
WO2007101698A2 (en) * 2006-03-09 2007-09-13 Aplagen Gmbh Modified molecules which promote hematopoiesis
EP2134862A4 (en) * 2007-03-12 2011-04-20 Univ Utah Res Found COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF DIABETIC MICROVASCULAR COMPLICATIONS
SG188161A1 (en) 2008-01-22 2013-03-28 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
CA2712606A1 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
CN102232085A (zh) 2008-09-26 2011-11-02 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
KR102233664B1 (ko) * 2012-12-05 2021-04-02 노파르티스 아게 Epo를 표적화하는 항체에 대한 조성물 및 방법
ES2913530T3 (es) 2015-08-12 2022-06-02 Novartis Ag Métodos para tratar trastornos oftálmicos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56145222A (en) * 1980-04-28 1981-11-11 Toshiyuki Hamaoka Improved antibody and its preparation
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4748018A (en) * 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
US4558005A (en) * 1982-09-13 1985-12-10 University Patents, Inc. Monoclonal anti-erythropoietin
US4558006A (en) * 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4677195A (en) * 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions

Also Published As

Publication number Publication date
JP3155002B2 (ja) 2001-04-09
DE59010787D1 (de) 1998-02-05
US5106954A (en) 1992-04-21
US5712370A (en) 1998-01-27
CA2021912C (en) 2001-11-27
ATE161577T1 (de) 1998-01-15
PT94813A (pt) 1991-03-20
CA2021912A1 (en) 1991-01-27
KR0175657B1 (ko) 1999-04-01
DE3924746A1 (de) 1991-01-31
EP0410246A1 (de) 1991-01-30
IE902707A1 (en) 1991-02-27
AU648506B2 (en) 1994-04-28
AU5977890A (en) 1991-01-31
KR910002897A (ko) 1991-02-26
EP0410246B1 (de) 1997-12-29
PT94813B (pt) 1997-04-30
GR3026096T3 (en) 1998-05-29
JPH0381294A (ja) 1991-04-05
DK0410246T3 (da) 1998-08-31

Similar Documents

Publication Publication Date Title
ES2111524T3 (es) Peptidos de eritropoyetina (epo) y anticuerpos dirigidos contra ellos.
ES2082775T3 (es) Anticuerpos de proteinas latentes de papilomavirus humano, sistemas de diagnostico y procedimientos.
WO1996029605A3 (en) Compounds and methods for the dectection of t. cruzi infection
ES2062971T3 (es) Peptidos de la cubierta de htlv iii.
NO910209L (no) Fremgangsmaate for fremstilling av rekombinante humane anti-cd18-antistoffer.
NO870476L (no) Fremgangsmaate for fremstilling av kryss-beskyttende humane monoklonale antistoffpreparater.
ATE171473T1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
DE3689948D1 (de) Monoklonale antikörper und testverfahren.
DK172686A (da) Antigen opnaaet ud fra humant vaev, fremgangsmaade til under anvendelse af antigenet at fremstille monoklonale antistoffer til diagnose og behandling af cancer, fremgangsmaade til paavisning af cancer, samt antistoffer mod antigenet
NO873774D0 (no) Monoklonale eller polyklonale antistoffer.
SE9201281D0 (sv) New human monoclonal antibodies, and a method for preparation thereof
DK69690D0 (da) Humane anti-rh(d) monoklonale antistoffer
GR3007000T3 (es)
DE69028561D1 (de) Immunoassay zum Nachweis von Antikörpern gegen HIV
DE69228739D1 (de) Immunoassay und monoklonaler antikörper zum nachweis von diarrhetischem schalentiergift
DK69590D0 (da) Humane anti-rh(d) monoklonale antistoffer
ES1009600Y (es) Dispositivo de fijacion de elementos sensores.
BR9007071A (pt) Anticorpos de anti-idiotipos que reagem com idiotopos divididos,expressos por linfomas humanos e auto-anticorpo
NO974852L (no) Humant <beta>2-integrin-<alfa>-subenhet
ZA903854B (en) Diagnostic test for detecting antibodies directed against antigens of one or more related viruses
DK362087D0 (da) Method for a rapid and sensitive detection of early appearing antibodies against retroviruses, as well as igg antibodies against certain retroviruses
NO900092L (no) Et ekspresjonssystem for fremstilling av kimeriske monoklonale antistoffer.
IL83422A (en) Method for the detection of human b lymphotropic virus antibodies
NO912050D0 (no) Sensor for optisk undersoekelse.
DK630189D0 (da) Fremgangsmaade og diagnosesaet til paavisning af antistoffer samt vandig vaskevaeske til brug herved

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 410246

Country of ref document: ES